Archive for the ‘Gene Therapy Research’ Category

SCOTTSDALE, AZ--(Marketwire - Jan 15, 2013) - Sage North America today announced AgReliant Genetics, LLC, a Midwestern field seeds company, has used a customized version of Sage SalesLogix on iPad tablets to achieve 95% CRM adoption among its 300 sales employees and accelerate its sales and marketing processes. AgReliant Genetics, which recently became the third-largest U.S. corn seed company, cites Sage SalesLogix as a key contributor to its growth.

"Sage SalesLogix helps our reps reduce 'windshield' time and prioritize visits with customers most likely to buy," said Steve Thompson, AgReliant Genetics director of IT. "We needed a way for reps to work more comfortably out in the field and still access CRM data. With Sage SalesLogix running on iPad tablets, they have everything needed from territory maps that drill into account details to speech-to-text notes that go right into the CRM database. Our sales and customer satisfaction have improved because reps can now manage most opportunities or issues right on location."

AgReliant Genetics markets five seed brands in Midwestern corn and soybean states. Each representative works with a customer base of farmers, dealers and retail operations, traveling approximately 50,000 miles a year while working out of their trucks to service territories. Prior to implementing Sage SalesLogix, sales representatives across all five brands used individual selling processes.

The company's initial CRM deployment showed management the importance of collecting detailed prospect and customer information, managing seed orders in CRM from its fulfillment system, scoring prospects for sales prioritization, and automating marketing campaigns. However, user adoption was just 5 percent due to the inconvenience of carrying laptops in the field.

AgReliant Genetics' IT team and Sage business partner, Sincera Solutions, developed a customized Sage SalesLogix iPad app, piloting a mobile CRM program with a cross section of employees. Within six months, Sage SalesLogix became a companywide CRM system with usage near 95% of sales employees.

In the field

AgReliant Genetics sales reps prefer visuals over to-do lists, so IT has made most CRM capabilities mobile, visual, voice-activated and keyboardless. The company provides iPad tablets to each sales rep, and security provisions include the ability to remotely wipe any tablet that is lost or stolen.

On average, reps will call on over 300 farmers a year. The reps use Google Maps on their iPad tablets with color-coded pins' visualizing Sage SalesLogix data to indicate each farming account's current acreage, how recently seed was purchased, and each farmer's unique agronomic specifications including soil type and equipment preferences. Pin colors also change to indicate new sales opportunity forecasts based on previous units purchased.

Another tablet status view indicates where each opportunity is in the sales process (orders pending, shipping, follow-up status and so on). Additional data visualizations show which prospects and customers are in specific stages of marketing campaigns so sales reps can determine exactly whom to call on next. Sage SalesLogix also shows reps which customers and prospects are purchasing seed from competitors.

A speech-to-text call note capability is the most popular among sales reps. They can simply speak into their tablets after sales visits, and notes are automatically transcribed into the appropriate Sage SalesLogix contact, account, opportunity and to-do fields.

View post:
AgReliant Genetics, LLC Using Sage SalesLogix CRM on iPad Tablets to Accelerate Sales and Improve Customer Experience

Jan. 15, 2013 Usually, results from a new study help scientists inch their way toward an answer whether they are battling a health problem or are on the verge of a technological breakthrough. Once in a while, those results give them a giant leap forward. In a preliminary study in a canine model of Duchenne muscular dystrophy (DMD), University of Missouri scientists showed exactly such a leap using gene therapy to treat muscular dystrophy.

The results of the study will be published in the journal Molecular Therapy on Jan. 15, 2013.

Muscular dystrophy occurs when damaged muscle tissue is replaced with fibrous, bony or fatty tissue and loses function. Duchenne muscular dystrophy is the most common type of muscular dystrophy predominantly affecting boys. Patients with DMD have a gene mutation that disrupts the production of dystrophin, a protein essential for muscle cell survival and function. Absence of dystrophin starts a chain reaction that eventually leads to muscle cell degeneration and death. For years, scientists have been working to find the key to restoring dystrophin, but they have faced many challenges.

One of the largest hurdles in DMD gene therapy is the large size of the gene. Dystrophin is the largest gene in the human genome, containing approximately 4,000 amino acids. To fit the dystrophin gene into a vehicle that could deliver the gene to the appropriate site in the body, one has to delete 70 percent of the gene. The highly abbreviated gene is known as the "micro-dystrophin" gene. Previous studies suggest that micro-dystrophin can effectively stop muscle disease in mice that are missing dystrophin. However, mice that are missing dystrophin show minimal DMD symptoms, and results from mice often do not predict what will happen in humans. In contrast to mice, loss of dystrophin results in severe muscular dystrophy in dogs. If micro-dystrophin can work in dystrophic dogs, it will likely work in human patients. Unfortunately, when micro-dystrophin was tested in dogs in previous studies, it was not successful.

To overcome these hurdles, a team led by Dongsheng Duan, the Margaret Proctor Mulligan Professor in Medical Research at the MU School of Medicine, engineered a new micro-dystrophin gene that carries an important functional region missing in previously tested micro-dystrophins.

"We placed the new microgene into a virus and then injected the virus into dystrophic dogs' muscles," Duan said. Following gene therapy, Duan's team examined the dogs for signs of muscle disease and measured muscle force in treated and untreated dogs. After careful evaluation of 22 dogs, Duan and colleagues found that the new version of micro-dystrophin not only reduced inflammation and fibrosis, it also effectively improved muscle strength.

"This is the first time that we have seen positive gene therapy results in large mammals of DMD," said Duan. "We still have a lot of work to do, but we now know that our gene therapy strategy works in large mammals; this is a quantum leap forward in fighting this disease. Our next step is to test our strategy in a large group of muscles in the dogs, and then, eventually, see if 'whole body therapy' will work in the dogs. We are still a long way off before we will have a human treatment, but with this finding, I do see a light at the end of this tunnel."

If additional studies, including animal studies, are successful within the next few years, MU officials would request authority from the federal government to begin human drug development (this is commonly referred to as the "investigative new drug" status). After this status has been granted, researchers may conduct human clinical trials with the hope of developing new treatments for Duchenne muscular dystrophy.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

See more here:
Quantum leap in gene therapy of Duchenne muscular dystrophy

Ovation Cell Therapy: Sell an Invention
This is for bioligy

By: Nucleusforpres

See original here:
Ovation Cell Therapy: Sell an Invention - Video

Ovation Cell Therapy 2 Year Update.
It #39;s my bday today yay *****HD IS AVAILABLE HERE**** Hi Beauties Beaus great seeing you and I hope you enjoy the video. I appreciate any feedback, suggestions and yes I take request. If you haven #39;t already please click the pretty subscribe button the like button if you saw something nice. See ya soon!!! All Business inquiries reviews, sponsors may feel free to contact me via email at ginaworks4u@att.net or gfancybeauty@gmail.com ^^^^Where You Can Find Me^^^^ FB-Regina Gfancybeauty Campbell Instagram-Gfancybeauty Twitter-Luvofawoman DISCLAIMER: I am in no way affiliated with any products shown though out this video. All items shown in this video were purchased for my own personal use as well as for educational purposes on Youtube.

By: Gfancybeauty

More here:
Ovation Cell Therapy 2 Year Update. - Video

W ORCESTER Guangping Gao, an accomplished scientist, makes the trip at least one time a day, and sometimes as many as five.

Each time he wants to confer with a colleague at the University of Massachusetts Medical School, each time he walks from his lab on Plantation Street to the main campus, he loses 10 or 15 minutes.

It's not much of a sacrifice in the name of science, acknowledged Mr. Gao, director of the school's Gene Therapy Center, which is developing a treatment for a fatal condition called Canavan disease.

But it's also far from ideal. Soon, Mr. Gao will move into the Albert Sherman Center, a vast, $400 million research building UMass Medical School constructed to double its research capacity and bring dozens of scientists under one roof.

I believe moving for us will make a huge difference, Mr. Gao said. I think this move will speed up our collaboration.

The Sherman Center was designed with collaboration in mind. The design team even made a staircase a central feature of the 500,000-square-foot, nine-story structure, to encourage chance meetings. They put wet and dry laboratory spaces on the same floors, so researchers working at lab benches and researchers crunching data on computers would be able to mingle.

This building is meant to bring people together, said Mark N. Dolny, associate principal with Architectural Resources Cambridge, which designed the building.

Set to open this month, the Sherman Center will be the new hub of the medical school campus, which also includes a main building and the Aaron Lazare Medical Research Building. The Sherman Center has ample lab space, cozy student meeting rooms, an airy dining area, a new fitness center and what Dr. Michael F. Collins, chancellor of the medical school, calls classy spaces where school leaders can try to impress potential donors.

UMass' goal for the Sherman Center is as huge as the building itself.

We're going to change the course of the history of diseases, Dr. Collins said.

Read more here:
Research takes center stage

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/kr5v5v/dna_sequencing) has announced the addition of Jain PharmaBiotech's new report "DNA Sequencing - Technologies, Markets and Companies" to their offering.

This report briefly reviews basics of human genome variations, development of sequencing technologies, and their applications. Current large and small sequencers are described as well as companies developing them. Various applications of sequencing are described including those for genetics, medical diagnostics, drug discovery and cancer. Next generation sequencing technologies, both second and third generations, are reviewed. Companies developing software for analysis of sequencing data are also included. Selected academic institutes conducting research in sequencing are also listed.

Current market is mostly for research applications and future markets will be other applications related to healthcare. The value of DNA sequencer market in 2012 is described with estimates for 2017 and 2022. Various methods and factors on which market estimates depend are described briefly. Small sequencers form the basis of SWOT (strengths, weaknesses, opportunities, threats) analysis. Several marketing strategies have been outlined.

The report includes profiles of 106 companies involved in sequencing and their 106 collaborations. The report text is supplemented by 33 tables, 12 figures and 300 selected references to the literature.

Key Topics Covered:

Executive Summary

1. Introduction

2. DNA Sequencing Technologies

3. Comparative Analysis of Sequencing Technologies

Here is the original post:
Research and Markets: DNA Sequencing - Technologies, Markets and Companies 2013 Report

Public release date: 14-Jan-2013 [ | E-mail | Share ]

Contact: Dr. Sibylle Kohlstdt s.kohlstaedt@dkfz.de Helmholtz Association of German Research Centres

Cachexia or wasting is a condition affecting up to 70 percent of cancer patients, depending on the type of cancer. It is characterized by a dramatic loss of body weight that is independent of food intake. Cachexia is seen particularly often and most pronounced in patients suffering from cancers of the digestive tract and the lungs. They may lose up to 80 percent of body fat and skeletal muscle. Muscle loss leads to weakness and immobility of patients and poorer response to treatment. An estimated 20 percent of cancer deaths are considered to be a direct consequence of cachexia, with failure of the respiratory muscles as a frequent cause of death.

"Doctors used to believe that cancer re-programs metabolism in such a way that all energy goes into tumor growth," says Prof. Dr. Stephan Herzig, who heads a joint research department of the German Cancer Research Center (DKFZ), Heidelberg University and Heidelberg University Hospital. However, by now researchers presume that cachexia is the body's response to various harmful stimuli originating directly from the growing tumor. In his endeavor to find the causes of cachexia, Stephan Herzig, an expert in metabolism, took a closer look at the liver as the control center of metabolism for the first time. "Cachexia patients frequently have an inflamed fatty liver this was a major clue for this organ being involved."

The researchers discovered that cancerous mice have extremely low lipid (blood fat) levels meaning that their bodies lack the most important energy source. However, they accumulate fat in the liver. The low lipid levels in the diseased animals are due to their liver releasing only very little VLDL (very low density lipoprotein). This lipoprotein is the vehicle that transports fats in the blood. Moreover, the genes for all major steps of lipogenesis are blocked in the livers of cancerous mice.

"This is a clear indication of a central gene switch in the liver driving cachexia", says Stephan Herzig. The researcher therefore specifically searched for differences in protein switches regulating gene activity and hence hepatic energy metabolism in cancerous and healthy mice. Herzig's team found significant differences in a poorly studied gene switch called TSC22D4, which is found in larger amounts in cancerous mice than in healthy control mice.

Herzig's team demonstrated the key role of TSC22D4 in the onset of cachexia. The researchers specifically silenced the switch in the animals' livers. The organ subsequently went back to producing enough VLDL to make lipid levels in the cancerous animals rise. In addition, the genes involved in lipogenesis got boosted again.

"Our results prove, for the first time, that dramatic loss of body mass may be controlled by the liver," says Stephan Herzig. "We also know by now that TSC22D4 has exactly the same effect in human hepatic cells. There is evidence suggesting that this gene switch can be controlled via specific metabolic products and that we might thus be able to slow down the fatal wasting process. However, this approach has not yet been proven experimentally. This is what we will investigate next."

###

Allan Jones, Kilian Friedrich, Maria Rohm, Michaela Schfer, Carolyn Algire, Philipp Kulozik, Oksana Seibert, Karin Mller-Decker, Tjeerd Sijmonsma, Daniela Strzoda, Carsten Sticht, Norbert Gretz, Geesje M. Dallinga-Thie, Barbara Leuchs, Manfred Kgl, Wolfgang Stremmel, Mauricio Berriel Diaz and Stephan Herzig: Transforming growth factor-beta1 Stimulated Clone-22 D4 is a molecular output of hepatic wasting metabolism, EMBO Molecular Medicine 2012

Read this article:
Liver controls wasting in cancer

Washington, Jan 14 (ANI): The tumor suppressor gene p53 is the single most frequently mutated gene in human tumors, as it keeps pre-cancerous cells in check by causing cells, among other things, to become senescent - aging at the cellular level.

Loss of p53 causes cells to ignore the cellular signals that would normally make mutant or damaged cells die or stop growing.

In short, the p53 pathway is an obvious and attractive target for drug developers.

But that strategy has so far proven difficult, as most p53 regulatory proteins operate via protein-protein interactions, which make for poor drug targets, as opposed to ones based on enzymes.

Now, a team of researchers from the Perelman School of Medicine, University of Pennsylvania, has identified a class of p53 target genes and regulatory molecules that represent more promising therapeutic candidates.

As Xiaolu Yang, PhD, professor of Cancer Biology and investigator in Penn's Abramson Family Cancer Research Institute, and his team describe, p53 participates in a molecular feedback circuit with malic enzymes, thereby showing that p53 activity is also involved in regulating metabolism.(The Yang lab identified p53's role in glucose metabolism in the past.)

The new findings suggest that p53 acts as a molecular sensor of metabolic stress and explains how metabolic stress can lead to senescence in cells, Yang said.

"We uncovered an important regulatory mechanism for p53 as well as an effector mechanism for p53," Yang said.

As cells become damaged and precancerous, the p53 protein prevents those cells from continuing towards becoming tumors by causing the cells to senesce.

Metabolic cues also regulate senescence, but the molecular relays coupling those two processes-senescence and metabolism-remained unknown.

More here:
Tumor suppressor gene links metabolism with cellular aging

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/s4wm4g/genetic_testing) has announced the addition of GlobalData's new report "Genetic Testing Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018" to their offering.

This new report provides key market data on the Genetic Testing market in the BRICS countries. The report provides value ($m), volume (units) and average price ($) data for each segment and sub-segment within seven market categories - Inborn Gene or Chromosome Alterations, Other Genetic Tests and Acquired Gene or Chromosome Alterations. The report also provides company shares and distribution shares data for the overall Genetic Testing market in each of the aforementioned countries. The report is also supplemented with global corporate-level profiles of the key market participants with information on key developments, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The emerging economies, comprising China, India, Brazil, Russia and South Africa, with a significantly large pool of under-served patients, represent the next big opportunity for the leading medical equipment and devices manufacturers. China remains the world's most populous country and is consequently home to a large patient base. The country is home to more than 120 million people who are aged 65 or oldera population in continuous need of medical care. India, the second most populous country globally, is home to 1.2 billion people, approximately 5% of which are aged 65 or older. It's estimated that shortly after 2020, India's population will surpass China, making it the most populous country in the world. As the population continues to grow and people continue to age, the underlying demand for healthcare is also expected to increase.

Scope

- Market size data for Genetic Testing market categories - Inborn Gene or Chromosome Alterations, Other Genetic Tests and Acquired Gene or Chromosome Alterations

- Annualized market revenues ($m), volume (units) and average price ($) data for each of the segments and sub-segments within the seven market categories. Data from 2004 to 2011, forecast forward for seven years to 2018.

- 2011 company shares and distribution shares data for the overall Genetic Testing market in each of the aforementioned countries.

- Global corporate-level profiles of key companies operating within the Genetic Testing market in BRICS.

View original post here:
Research and Markets: Genetic Testing Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018

Public release date: 13-Jan-2013 [ | E-mail | Share ]

Contact: Karen Kreeger karen.kreeger@uphs.upenn.edu 215-349-5658 University of Pennsylvania School of Medicine

PHILADELPHIA - It is perhaps impossible to overstate the importance of the tumor suppressor gene p53. It is the single most frequently mutated gene in human tumors. p53 keeps pre-cancerous cells in check by causing cells, among other things, to become senescent aging at the cellular level. Loss of p53 causes cells to ignore the cellular signals that would normally make mutant or damaged cells die or stop growing.

In short, the p53 pathway is an obvious and attractive target for drug developers. But that strategy has so far proven difficult, as most p53 regulatory proteins operate via protein-protein interactions, which make for poor drug targets, as opposed to ones based on enzymes.

Now, a team of researchers from the Perelman School of Medicine, University of Pennsylvania, has identified a class of p53 target genes and regulatory molecules that represent more promising therapeutic candidates.

As Xiaolu Yang, PhD, professor of Cancer Biology and investigator in Penn's Abramson Family Cancer Research Institute, and his team describe in an advance online Nature publication, p53 participates in a molecular feedback circuit with malic enzymes, thereby showing that p53 activity is also involved in regulating metabolism.(The Yang lab identified p53's role in glucose metabolism in the past.)

The new findings, Yang says, suggest that p53 acts as a molecular sensor of metabolic stress and explains how metabolic stress can lead to senescence in cells.

"We uncovered an important regulatory mechanism for p53 as well as an effector mechanism for p53," Yang says.

Significantly, the findings also identify malic enzymes as novel and potentially useful pharmaceutical targets for anticancer therapy, as well as possible mediators of the normal aging process though neither possibility was actually addressed in the current study.

As cells become damaged and precancerous, the p53 protein prevents those cells from continuing towards becoming tumors by causing the cells to senesce. Metabolic cues also regulate senescence, but the molecular relays coupling those two processes -- senescence and metabolism -- remained unknown.

Visit link:
Cancer suppressor gene links metabolism with cellular aging

7th Grade Science Project Genetic Engineering Hour 6 Mrs. Lindahl
Hi! I #39;m really hungry right now. Haha.

By: Annie Ross

Follow this link:
7th Grade Science Project Genetic Engineering Hour 6 Mrs. Lindahl - Video

7th Grade Science Project on Genetic Engineering Mrs Lindahl Hour 6
Sorry. My brothers are really immature. :^)

By: Annie Ross

See the original post:
7th Grade Science Project on Genetic Engineering Mrs Lindahl Hour 6 - Video

LANSING, Mich., Jan. 14, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (KBLB) (the "Company" or "Kraig") announced that researchers, working pursuant to Kraig's collaborative research program, utilizing customized spider silk genetic engineering sequences, succeeded in creating a new type of recombinant spider silk, which the Company is designating as "Big Red."

The "Big Red" silk is currently being spun within the laboratory by transgenicly modified silkworms.

"'Big Red' is a composite fiber," said Company CEO, Kim Thompson. "This new type of fiber was designed to be a combination of spider silk proteins, silkworm silk proteins and protein from an unrelated species. From a genetic perspective, what significantly differentiates this material from our Monster Silk(TM) is the unique spider silk genetic sequence that we used, which we designed to increase strength to weight ratios. Another important difference is the incorporation of a unique protein, which gives the new fiber its designation as 'red.'

"The design for 'Big Red' derived from what we learned about the mechanical characteristics of recombinant spider silk fibers from our work with Monster Silk(TM)," continued Thompson. "Specifically, the new fiber was designed to place more emphasis on tensile strength and slightly less emphasis on elongation. We anticipate that 'Big Red' will be a powerful arrow in our quiver as we move to commercialize Monster Silk(TM) and the Company is hopeful that this new material will follow it in the commercialization pipeline. In my view, the creation of Big Red demonstrates the power of our technology to continue to develop new and exciting materials."

The "Big Red" name comes in part from the fact that the fibers have a slight red cast. Under UV light, the new fibers actually glow bright red.

Thompson further stated, "The successful creation of these new materials once again validates our scientific models. Based upon the observed levels of color expression and the nature of the spider silk genetic configurations used in its creation, the hope is that it will find its own significant niche in the technical textiles marketplace. Preparation for mechanical testing of the new fiber is currently taking place."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

View original post here:
Kraig Biocraft Laboratories Announces the Creation of New Recombinant Spider Silks

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/ft27lp/animal) has announced the addition of Jain PharmaBiotech's new report "Animal Biotechnology - Technologies, Markets and Companies" to their offering.

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology.

Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals.There is discussion of in vitro meat production by culture

Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans.RNA interference technology is now being applied for research in veterinary medicine

Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics.

Biotechnology products are approved by the Center for Veterinary Medicine of the FDA. Regulatory issues relevant to animal biotechnology are described.

Approximately 110 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 108 collaborations in this area are shown.

Share of biotechnology-based products and services in 2012 is analyzed and the market is projected to 2022.

The text is supplemented with 34 tables and 5 figures.Selected 250 references from the literature are appended.

See more here:
Research and Markets: 2013 Animal Biotechnology - Technologies, Markets and Companies

By Prachiti Dalvi

Structure of Codeine

Codeine is an opioid pain medication; but if you are a poor metabolizer of a particular enzyme (CYP2D6), you will experience no pain relief from this drug. However, if your doctor could administer something called pharmacogenetic testing, she would know to simply give you morphine (an active metabolite of codeine) instead. For now, this kind of testing isnt available.

Mary Relling, PharmD

Mary V. Relling, PharmD, the Chair of Pharmaceutical Sciences at St. Judes Children Hospital spoke about the need to implement pharmacogenetic testingon Thursday, January 10. A number of tests have recently emerged that are ready for prime time. When we know that some drugs may have adverse effects for people with particular genetic phenotypes, it is unethical to prescribe these drugs without knowing the patients genetic status.

However, Relling said there are a number of barriers to integrating pharmacogenetic tests into clinical care: fragmentation of our healthcare system, a focus on sick-care rather than disease prevention, a lack of evidence for clinical utility or cost-effectiveness, complex underlying lab results, and a lack of a centralized system for recording patient information.

The best way to break through these barriers is to conduct testing preemptively, Relling said. We can simply take drop of blood when the baby is born and run genetic tests. Genetic tests are lifetime results. It makes sense to have it in the background, just as we know a patients age, weight, sex, etc., Relling said. The barriers discussed above can be avoided to a certain extent at St. Judes because they have adopted a team approach to patient care and a 100% electronic system for recording patient records.

The growing affordability of genotyping makes using preemptive pharmacogenetic testing more feasible, she said. The cost of sequencing one or two genes in the past will now produce results for 225 genes. Two years ago, theClinical Pharmacogenetics Implementation Consortium (CPIC)studied how tomigrate pharmacogenetic testing from the laboratory into routine patient care. They looked for gene-drug pairs associated with potential risks oflife-threatening toxicity, serious adverse effects, or lack of effectiveness.Eleven of the genes CPIC determined met the threshold for high-risk were found to have profound effects on 33 drugs.

Relling said approximately 48% of patients receiving drugs at St. Judes received orders for at least one of those pharmacogenetically high-risk medications.

She said the question now is how to usegenetic test results rather than whether a genetic test should be ordered. In the coming years, we will have to address how to maintain the fine balance of providing the clinician with enough information to treat the patient and overwhelming the patient with genetic testing results that are difficult to interpret.

See the rest here:
A Call for Action: Genetic Testing Before Prescriptions

Bikini Bottom Genetics #5.17
Bikini Bottom Genetics #5.17

By: MrGarrettbenjamin

Follow this link:
Bikini Bottom Genetics #5.17 - Video

My Slideshow querkle tga genetics
week 6

By: jeffry blodem

Visit link:
My Slideshow querkle tga genetics - Video

Genetics Problems (Monohybrid) #5.21
Genetics Problems (Monohybrid) #5.21

By: MrGarrettbenjamin

Continue reading here:
Genetics Problems (Monohybrid) #5.21 - Video

Uno Lady- Yellow Mustard Submarine
Video recorded and edited by Carmen Navis. Yellow Mustard Submarine written and recorded by Uno Lady. From the 2009 tape release, I really like genetics but I #39;d rather have a good time. Video from Tower 2012 bus tour to Detroit, MI and the Flower Shop in Chicago, IL. http://www.unolady.com

By: TheUnoLady

See more here:
Uno Lady- Yellow Mustard Submarine - Video

Study Guide Genetics Mitosis Meiosis #5.25
Study Guide Genetics Mitosis Meiosis #5.25

By: MrGarrettbenjamin

Original post:
Study Guide Genetics Mitosis Meiosis #5.25 - Video

MaddFarmer Genetics Urkle Queen
Grown by ~H~

By: Dublin Skunkfiend

See more here:
MaddFarmer Genetics Urkle Queen - Video

Yoga Teacher Gets Double Mastectomy to Avoid Breast Cancer | Inner Visions, Outer Triumphs
http://www.stoneweardesigns.com. Yoga teacher, long-time yoga practitioner, mother, wife, former corporate employee, Emily Goble tested positive for both breast cancer and ovarian cancer genetics. Because her mother has struggled with eight different types of cancer over 25 years and Goble was 87% likely to get breast cancer and 90% for ovarian, she voluntarily opted for a double mastectomy and will soon be undergoing a voluntary hysterectomy. Wow. Check out the Inner Visions, Outer Triumphs video for more on her extraordinary journey. The article below focuses on Goble #39;s yoga teaching and the support her students offered her through the process. Read more at http://www.livestonewear.com

By: StonewearDesigns

Read the original post:
Yoga Teacher Gets Double Mastectomy to Avoid Breast Cancer | Inner Visions, Outer Triumphs - Video

Copy of MaddFarmer Genetics Urkle Queen
Grown by ~H~

By: Dublin Skunkfiend

View original post here:
Copy of MaddFarmer Genetics Urkle Queen - Video

Fallout 3 Awesome Adventures Part 1: Black Dad
I find out about the ways of genetics of birth and have fun doing it! Along with some physics and bad parenting skills so enjoy!

By: AwesomeMat64

Read the rest here:
Fallout 3 Awesome Adventures Part 1: Black Dad - Video

Apa itu Fastabiqul Khairat?
soundtrack : First Breath After Coma - Explosion In The Sky credit to seniors involved : Bro Firdaus ASIS 3rd year - Ecology Biodiversity Bro Hanif ASIS 3rd year - Microbiology Sis Andi Nur Hazirah ASIS 3rd year - Biohealth Sis Fatimah Zahra SEMPIS 1st year - Genetics Molecular Biology

By: KerabatAPIDS

Continue reading here:
Apa itu Fastabiqul Khairat? - Video